	US 12,344,673 B2
	Medicaments, uses and methods
Björn Frendéus, Landskrona (SE); Ingrid Teige, Lund (SE); Linda Mårtensson, Bjärred (SE); Mark Cragg, Southampton (GB); and Ali Roghanian, Southampton (GB)
Assigned to BIOINVENT INTERNATIONAL AB, Lund (SE)
Appl. No. 15/311,016
Filed by BIOINVENT INTERNATIONAL AB, Lund (SE)
PCT Filed May 15, 2015, PCT No. PCT/EP2015/060744 § 371(c)(1), (2) Date Nov. 14, 2016, PCT Pub. No. WO2015/173384, PCT Pub. Date Nov. 19, 2015.
Claims priority of application No. 1408673 (GB), filed on May 15, 2014.
Prior Publication US 2017/0107293 A1, Apr. 20, 2017
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2887 (2013.01) [A61K 9/0034 (2013.01); A61K 9/0048 (2013.01); A61K 9/0095 (2013.01); A61K 9/02 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); C07K 16/283 (2013.01); C07K 16/2893 (2013.01); C07K 16/30 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

14 Claims

1. A method of treating relapsed B-cell cancer in a subject, the method comprising administering:

(i) a first antibody molecule selected from the group consisting of rituximab and obinutuzumab; in combination with

(ii) a second antibody molecule that prevents or reduces FcγRIIb present on the target B-cell from binding to the Fc domain of the first antibody molecule, and prevents or reduces internalization of the first antibody molecule into the target B-cell wherein the second antibody molecule specifically binds FcγRIIb, wherein the second antibody molecule is an antibody; a chimeric antibody; a single chain antibody; a Fab, F(ab′)₂, a Fv, a ScFv or a dAb antibody fragment;

an IgG2 antibody; an IgG4 antibody; a chimeric molecule of IgG2 and IgG4; an antibody variant comprising a N297Q mutation; or a DANA variant antibody; and wherein the second antibody comprises the following CDR amino acid sequences: SEQ ID NO: 171 and SEQ ID NO: 172 and SEQ ID NO: 173 and SEQ ID NO: 174 and SEQ ID NO: 175 and SEQ ID NO: 176;

wherein that the subject is selected on the basis that the subject has relapsed B-cell cancer, wherein the relapsed B-cell cancer is resistant to treatment with the first antibody molecule, wherein the subject has previously been treated with the first antibody molecule and has previously responded to the treatment, and subsequently relapsed, and that the subject has target B-cells that express FcγRIIb, and wherein the B-cell cancer is selected from the group consisting of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).